Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
Roberta Gualtierotti, Associate Professor of Internal Medicine at University of Milan, shared on LinkedIn:
”Fc-fusion factors in orthopaedic surgery for haemophilia
Happy to share our experience at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Ospedale Policlinico di Milano, Università degli Studi di Milano, and Florence Hemophilia Center, Azienda Ospedaliero-Universitaria Careggi.
Prospective study (2018–2023) on 20 major surgeries in 19 patients with haemophilia A or B treated with rFVIIIFc or rFIXFc.
- Haemostasis rated ‘good’ in 95% of cases
- No transfusions required
- No treatment-related adverse events
- we need more date to standardize and personalize perioperative schedule with EHL factors
Conclusion: rFVIIIFc and rFIXFc ensured effective haemostasis and favourable safety in major orthopaedic surgery.”
Title: Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half-Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
Authors: Luigi Piero Solimeno, Roberta Gualtierotti, Emanuele Guido, Jacopo Acquati Lozej, Enrica Cristini, Alessandro Ciavarella, Sara Arcudi, Christian Carulli, Lisa Pieri, Simona Maria Siboni, Flora Peyvandi
Read the full paper here.
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Oct 13, 2025, 03:53Ganesh Mohan is Organising a Webinar to Improve Awareness About Thrombophilia on World Thrombosis Day
-
Oct 13, 2025, 02:47Thomas Reiser: Don't Miss This ISTH Research Recap with Robert Sidonio, Cedric Hermans and Michael Makris
-
Oct 12, 2025, 15:39Renjith Vijayakumar Selvarani: A Heart Attack Isn’t Just a Health Scare — It’s a Medical Emergency
-
Oct 12, 2025, 11:28Is it time for GLP1 receptor agonists in VTE care?
-
Oct 12, 2025, 11:26WFH: Women and Girls with Bleeding Disorders
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 12, 2025, 01:32Evaluating Drug–Drug Interactions in Cancer Patients Receiving Anticoagulants and Antineoplastics
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
-
Oct 13, 2025, 03:15Arun V. J: They Chose Death Over A Blood Transfusion — And Here’s Why I Stopped Judging Them
-
Oct 13, 2025, 03:13Rahaf Ajaj: The Persistent Gender Gap in Nobel Prizes - A Call for Greater Inclusion
-
Oct 13, 2025, 02:50Emmanuel J Favaloro: Again Promoting World Thrombosis Day - October 13
-
Oct 12, 2025, 07:38Antonio Vega With Incredible Team Led by the Great Dr Majluf